Currently, many targeted therapies have been developed against IDH mutations.[4] Recently, ivosidenib (AG‐120) showed improved survival in patients with IDH1‐mutant ICC.[49] We found that a significant proportion of mutations in IDH1/2 were non‐truncal events across three independent cohorts (ICC_this study, 2/3; ICC_TCGA, 1/3; ICC_Dong et al. This evidence concerns the gene IDH1 and intrahepatic cholangiocarcinoma.